Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 24 (1), 2025
Pp 104 - 108

Development of Protocol for Inspecting Imported Medical Devices in the Kingdom of Saudi Arabia

[1]Sultan Badr AlDalbahi, [2]Omar Saad Aljohani , [3]Mansour Nasser H Yanbuawi, [4]Abdullah Mohammed Zabbani

King Abdulaziz University Dental Hospital and Armed Force Hospital in Jzazn

Received: 09 January 2025 **Revised:**17 February 2025 **Accepted:** 15 March 2025

Introduction

The Kingdom of Saudi Arabia's healthcare sector has experienced remarkable growth in recent years, with a significant increase in the importation of medical devices from global manufacturers. The expanding medical device market requires strong inspection procedures to safeguard patient welfare and device effectiveness and fulfill international and national requirements. As the lead regulator of medical devices in Saudi Arabia, the Saudi Food and Drug Authority (SFDA) faces the essential task of creating detailed inspection procedures that maintain rigorous quality assurance and facilitate smooth market entry. The inspection protocols need to manage devices with multiple complexity levels that enter Saudi Arabia since they range from simple disposables to complex diagnostic tools and embedded medical devices that require separate examination rules and dangerous treatments. Standardized inspection methods should integrate global best practices, Saudi Arabian healthcare needs, local regulations, and capabilities for inspecting modern medical devices.

Regulatory Framework and Legal Requirements

The Medical Devices Interim Regulation (MDIR), accompanied by its succeeding amendments, serves as the regulatory foundation that follows international standards, particularly those of the International Medical Device Regulators Forum (IMDRF), for medical device importation in Saudi Arabia. All medical devices coming into Saudi Arabia need prior approval from SFDA before market access by making sure manufacturers create technical documentation alongside clinical evidence documenting safety standards while obtaining quality system certifications (Almoteiry et al., 2022). The SFDA follows a regulatory approach that blends international standards with European Medical Device Regulation (MDR) and U.S. Food and Drug Administration (FDA) standards yet maintains unique Saudi Arabian provisions that address the country's healthcare needs and market characteristics. These regulations set up the legal requirements for inspection through their definition of essential requirements teamed with conformity assessment approaches and post-market surveillance duties for manufacturers and importers.

The legal framework establishes precise inspection power limits for SFDA officials to conduct unexpected site visits, product testing, and documentation examinations within all supply chain stages. Royal Decree M/76 widens its inspection powers by establishing sanctions, including monetary penalties, import bans, and market withdrawal orders for items of inadequate quality or counterfeited products. New Saudi Arabian government legislation boosts import control mechanisms through obligatory phasing out traditional documentation and implementing the SFDA Ghad electronic platform for risk evaluations before physical checks. Saudi Arabia needs to align with the medical device regulations of the Gulf Cooperation Council (GCC) since this membership requirement supports unified inspection practices throughout member nations. Regulatory authority and operational framework from the existing legal foundation enable specialists to create uniform inspection standards for every medical device that accesses Saudi Arabia.

Risk Classification of Medical Devices

Medical device risk categorization within Saudi Arabia consists of four classes that use international standards to classify devices from Class I (minimal risk) to Class IV (most significant risk). The classification depends on the level of invasiveness and duration of patient contact alongside estimated fallout risks from device failures. The regulation system determines inspection intensity because more dangerous devices demand in-depth documentation standards, stricter physical examination limits, and possible pre-release laboratory studies (World Health Organization, 2024). Non-sterile bandages and examination equipment like Class I devices need simplified document verifications and sample testing. Still, implantable cardiac instruments and insulin pumps under Class IV need complete technical file documentation plus specialized tests before market release. Saudi Arabian healthcare conditions, including climate factors affecting device performance and regional disease profiles, have led the SFDA to modify Global Harmonization Task Force (GHTF) rules for classification purposes.

The risk-based approach assesses electronic medical devices through multiple evolving factors, including manufacturer adherence records, country-specific safety trends, and worldwide medical alerts. The SFDA has established a Risk Evaluation Matrix, which generates an Overall Risk Score (ORS) through quantitative variable assessment to determine the depth of inspection of imported shipments. Device inspection intensity correlates directly to technological newness and material absence of market experience regardless of official classification. Through this precise risk assessment process, agencies direct their strongest inspections toward medical devices with significant potential harm to patients while enabling the smooth entry of safe devices with robust histories (Food, 2018). The inspection protocol has to contain explicit decision processes with algorithmic instructions to maintain equal application of risk-based evaluations at each entry point and by all personnel responsible for medical device inspections.

Pre-Import Documentation and Verification Procedures

Medical device importers must verify all required documents using the SFDA electronic platform beginning at least 30 days before shipment arrival for their products under the medical device inspection protocol's first stage. A medical device importer needs to present an official documentation bundle to the SFDA that combines the MDMA certificate alongside a Certificate of Conformity and Declaration of Conformity, verified technical file references, and GMP certificates from recognized testing bodies. Various supplementary requirements consist of batch certifications and sterilization validation documentation according to relevant guidelines, stability data validations for product quality under Saudi Arabia's climate, and verification of Arabic-language labeling content (Alghaith et al., 2020). The confirmation process utilizes automated database comparisons of submitted materials against the FDA's accepted products, and it verifies certificates through safe electronic connections to issuing organizations for document validity assessment. The first evaluation procedures enable authorities to determine which shipments need advanced inspection processes before their Saudi customs arrival.

Evaluation of documentation through standardized checklists determines compliance and consistency with present-day regulations and assigns Documentation Compliance Scores, thus affecting physical inspection criteria. Team members who specialize in this work compare the technical details of equipment to preapproved versions to find unauthorized changes that could create safety or performance risks. Businesses must inspect cybersecurity documents that evaluate electronic devices and software to determine their ability to resist potential threats that might impact operational functionality alongside patient data defense systems (Solaiman et al., 2024). The assessment method for pre-import verification consists of analyzing the importer's record of compliance and validating the correct temperature-specific transport requirements for temperature-sensitive devices. The phase reveals deficiencies through which the authorities demand supplementary documentation, while in some cases, it leads to third-party testing mandates before rejecting importation demands at the origin country. This rejection process protects the importer from returning non-compliant shipments and associated costs.

Post-Market Surveillance and Compliance Monitoring

The import inspection protocol gains its essential nature from post-market surveillance, which maintains an ongoing performance tracking system for medical devices during their Saudi market lifecycle. The SFDA has established a compulsory electronic reporting system for healthcare institutions and distributors, including manufacturers, to disclose device-related occurrences within periods decided by device severity. An active surveillance system contains facility inspections that specifically check newly imported devices to evaluate their real-world performance and find problems not seen during the import inspection (Alfageh et al., 2024).

Through its risk-based scheduling system, the surveillance program evaluates electronic devices according to their level of risk, together with newly available technologies and products from manufacturers who have failed to meet standards in the past. Data analytics tools analyze device performance measurements at multiple healthcare locations to alert medical safety authorities about potential quality failures missed during pre-market screening and first inspections.

The compliance monitoring framework incorporates periodic sampling of marketed devices for laboratory testing to verify continued conformity with registered specifications and performance standards. Healthcare facilities in Saudi Arabia enable checks to verify product stability from confirmed manufacturing times during their designated shelf life use period. Through international information-sharing agreements, the SFDA cooperates with regulatory agencies to detect global safety issues, allowing them to conduct specific product inspections of products in Saudi distribution channels when safety recalls are needed. Results from the post-market surveillance process lead to modifications in future inspection protocols for imported goods by modifying risk profiles and inspection processes for subsequent shipments from the same manufacturer. An integrated system uses field performance data to maintain continuous updates in the inspection procedure, creating an extensive quality control system that identifies medical devices from import until exit from Saudi markets.

Digital Tracking and Registration Systems

The National Drug and Medical Device Track and Trace System (NDMTTS) in Saudi Arabia employ GS1 standard identifiers and blockchain technology to establish an unalterable history of medical devices from their manufacturer until they reach the end-user. The system demands medical devices imported into the kingdom to carry UDI markings that permit electronic verification processes from each inspection point through all distribution stages, thus minimizing healthcare system contamination from counterfeit items. The digital platform links to customs databases while enabling automatic checks between import paperwork and permitted product certifications, which allows inspectors to view total device specifications, past evaluation records, and worldwide safety notifications in real-time (Elkhalifa et al., 2024). Real-time data exchanges between inspection personnel guarantee they get current unified information from every border station. This lets them enforce inspection methods identically, no matter their location while building a standardized database for evidence-based regulatory choices.

The digital system employs analytics tools to detect statistical trends in inspection results to identify particular manufacturer problems, product categories, and countries of origin that demand specific regulatory actions. Mobile applications support secure inspection processes by letting inspectors access the central database from field sites to upload results with images and get automated testing guidelines from the system based on instantaneous risk evaluation. IoT-integrated devices enable non-stop environmental parameter tracking of storage and transit conditions by sending automated warning alerts beyond specific range thresholds (Alhadlaq et al., 2023). Stakeholders receive fast inspection outcomes through secure online portals, cutting administrative work delays and maintaining all documentation requirements. The planned system improvement adds artificial intelligence elements that will generate predictive risk models combined with international and regional whole database access for establishing global active monitoring of medical device quality.

Stakeholder Roles and Training Requirements

Implementation success of medical device inspection protocols needs a proper definition of responsibilities for SFDA regulatory officials, customs authorities, third-party inspection bodies, importers, and healthcare providers. The SFDA maintains its role as the principal coordinating entity by developing inspection standards and providing personnel certification while monitoring periodic audits to maintain uniformity. Customs authorities must verify import documents first, as SFDA needs assistance for specialized medical device assessments requiring training about both device recognition and risk analysis.

The inspection function receives additional support from accredited third-party organizations that perform general testing of low-risk devices based on SFDA guidelines. At the same time, regulatory staff primarily assesses higher-risk devices and complex evaluations (Mashaki Ceyhan et al., 2028). Importers and manufacturer representatives bear responsibility for facilitating inspection processes by providing complete and accurate documentation, ensuring proper storage conditions during inspection periods, and responding promptly to information requests or identified non-conformities.

The inspection personnel training program is an essential foundation of the protocol because it mandates experts to finish an official certification process, which joins theoretical education about medical devices with regulatory rules and inspection protocols to practical field education supervised by experts. Education programs have device-specific modules that cover specialized sectors comprising diagnostic imaging equipment with implantable devices and in-vitro diagnostics to provide inspectors with technical expertise for various medical technology assessments. Champions of continuing education must demonstrate their competency yearly by passing assessments and finishing courses about new technologies and regulatory adjustments along with modern inspection methods (Tawfik et al., 2022). The SFDA maintains international educational partnerships through which Saudi inspectors can learn international best practices through exchange programs. Through the framework, experienced inspectors mentor new employees and lead regular inter-laboratory comparison exercises to maintain uniform testing standards during inspections at all facilities and produce highly expert personnel for complex inspection techniques with scientific accuracy.

Conclusion

Saudi Arabia undertook a strategic initiative to develop an extensive import medical device inspection protocol because it merges access to innovative healthcare technologies against the essential duty to protect patient safety and device performance standards. The complete framework provides a robust quality assurance system by uniting risk-based reviews with standardized site inspection documentation, continuous monitoring and digital system tracking, and expert inspectors' training. This protocol will enhance Saudi Arabia's regulatory capabilities and build trust among medical providers and patients while manufacturers from abroad. The framework's success requires investments in technological infrastructure, international regulatory collaborations, and specialized personnel development while inspectors regularly review methodology for emerging threats and new technology benefits. These collective efforts will enable Saudi Arabia to build a worldwide standard in medical device inspection that protects public health alongside the advancement and reforms of its national healthcare system.

References

1. Alfageh, B. H., Abanmy, N. O., Kentab, B. Y., & Almohammed, O. A. (2024). Overview of online pharmacy regulations in Saudi Arabia and the Gulf cooperation council countries and their impact on online pharmacy service providers in Saudi Arabia: a qualitative analysis. *Frontiers in Pharmacology*, *15*, 1380231. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1380231/full
2. Alghaith, T., Almoteiry, K., Alamri, A., Alluhidan, M., Alharf, A., Al-Hammad, B., ... & Alazemi, N. (2020). *Strengthening the pharmaceutical system in the Kingdom of Saudi Arabia: towards a medicine policy to support Vision 2030*. World Bank.

https://www.researchgate.net/profile/Mohammed-Alluhidan/publication/352879495_Strengthening_The_Pharmaceutical_System_In_the_Kingdom_of_Saudi_Arabia_Towards_A_Medicine_Policy_To_Support_Vision_2030/links/60ddac7092851ca9449e892c/Strengthening-The-Pharmaceutical-System-In-the-Kingdom-of-Saudi-Arabia-Towards-A-Medicine-Policy-To-Support-Vision-2030.pdf

3. Alhadlaq, M. A., Mujallad, M. I., & Alajel, S. M. (2023). Detection of Escherichia coli O157: H7 in imported meat products from Saudi Arabian ports in 2017. *Scientific Reports*, *13*(1), 4222. https://www.nature.com/articles/s41598-023-30486-2

4. Almoteiry, K., Alharf, A., Al Hammad, B., Aljuffali, I., Al-Azemi, N., Al-Ghaith, T., ... & Pisani, E. (2022). National medicines policy development, Saudi Arabia. *Bulletin of the World Health Organization*, *100*(8), 511. https://pmc.ncbi.nlm.nih.gov/articles/PMC9306383/

5. Elkhalifa, S. M., Altilmisani, N. M., Albishri, F., Gad, H. A., Al-Dubai, T. A., & Al-Wesabi, E. O. (2024). Overview of quality control and safety in public health pest laboratory in Jeddah, Saudi Arabia. *International Journal of Agriculture and Biosciences*, *13*(2), 92-100. https://www.ijagbio.com/pdf-files/IJAB-23-556.pdf

6. Food, S. (2018). Medical Devices Sector Saudi Food & Drug Authority. https://beta.sfda.gov.sa/sites/default/files/2019-10/MDS%E2%80%93G28_0.pdf

7. Mashaki Ceyhan, E., Gürsöz, H., Alkan, A., Coşkun, H., Koyuncu, O., & Walker, S. (2018). The Turkish medicines and medical devices agency: comparison of its registration process with Australia, Canada, Saudi Arabia, and Singapore. *Frontiers in pharmacology*, *9*, 9. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00009/full

8. Solaiman, B., Bashir, A., & Dieng, F. (2024). Regulating AI in health in the Middle East: case studies from Qatar, Saudi Arabia and the United Arab Emirates. In *Research handbook on health, AI and the law* (pp. 332-354). Edward Elgar Publishing. https://www.elgaronline.com/edcollchap-oa/book/9781802205657/ch19.xml

9. Tawfik, E. A., Tawfik, A. F., Alajmi, A. M., Badr, M. Y., Al-Jedai, A., Almozain, N. H., ... & Almalik, A. M. (2022). Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia. *Saudi Pharmaceutical Journal*, *30*(1), 28-38. https://www.sciencedirect.com/science/article/pii/S1319016421002498

10. World Health Organization. (2024). *WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory system of medical products: manual for benchmarking and formulation of institutional development plans*. World Health Organization. https://books.google.co.ke/books?hl=en&lr=&id=XaYOEQAAQBAJ&oi=fnd&pg=PR5&dq=Development+Of+Protocol+For+Inspecting+Imported+Medical+Devices+in+the+Kingdom+of+Saudi+Arabia&ots=OvMRweB0vj&sig=64l_O9YFiX-GGQQnAz_FId0_XRo&redir_esc=y#v=onepage&q&f=false